A New Antibiotic?

Scientists show that peptide-conjugated phosphorodiamidate morpholino oligomers can effectively silence essential bacterial genes.

By | October 16, 2013

Scanning electron micrograph of Acinetobacter baumanniiCDCA new type of antibiotic based on DNA/RNA analogs that silence the expression of specific bacterial genes is reported in The Journal of Infectious Diseases today (October 16) by researchers from Oregon State University (OSU), the University of Texas Southwestern Medical Center, and the Corvallis-based firm Sarepta Therapeutics. Called peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs), the compounds were effective at reducing the viability of Acinetobacter lwoffii and A. baumannii both in vitro and in infected mice.

“With infections from drug-resistant pathogens rising rapidly, there is an urgent need to come up with new approaches such as the use of PPMOs to spur antibiotic development,” study coauthor David Greenberg from UT Southwestern noted in a statement. “There is a lot of promise in developing new antibiotics that target specific pathogens as opposed to so-called broad-spectrum antibiotics that target whole classes of bacteria.”

Fierce Drug Delivery noted that a PPMO is  “essentially a synthetic form of microRNA,” such as those that have already been used to silence specific disease-causing genes. While further research is required before PPMOs move to clinical trials, the researchers said their approach shows promise for precisely targeting specific pathogens. “The mechanism that PPMOs use to kill bacteria is revolutionary,” OSU’s Bruce Geller, coauthor on the study, said in a statement. “They can be synthesized to target almost any gene, and in that way avoid the development of antibiotic resistance and the negative impacts sometimes associated with broad-spectrum antibiotics.”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Jon M

Jon M

Posts: 1

October 16, 2013

These PPMOs targeting Acinetobacter are based on a body of work using Morpholino oligos to target bacteria, much of it from Prof. Geller's lab. 

Avatar of: PastToTheFuture

PastToTheFuture

Posts: 85

October 17, 2013

Awesome, absolutely awesome. No, not so sexy, but awesome if you know the importance.

Avatar of: TBerg

TBerg

Posts: 2

January 14, 2017

In 2016, I treated five peyote cacti ( legal in Canada ) with silver solution and the intent of creating Super alkaloidal amines, amino acids, non-proteinic acids, phenylethamines, and isoquinolines for future reseach into its possible antibiotic action(s). What's needed for the analysis of my dry powdered peyote is a facility with a High Performance Thin Layer Chromatography machine to do it. I have made requests to tabs both nationally and internationally and all have refused as of this date for one reason or another or remained silent.  My hunch is that the antibiotic properties of  the plant  and mineral will introduce a whole new class of terpentines and/or triterpentines to research with and develop new drugs. All that I ask for is the right to have my peyote tested.  Refusing me is to ready ourselves to the upcoming post-antibiotic era with hopelessness. Time is running out and there is so little of it left.

Avatar of: TBerg

TBerg

Posts: 2

January 14, 2017

As of January 14, 2017. If you want to get my attention, I can be found here> timothyottoadamberg@gmail.com<

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Human Cord Plasma Protein Boosts Cognitive Function in Older Mice
AAAS